Home Antibody All anti-BCL2A1 antibodies
Also for BCL2A1 (NM_001114735)
|Bfl-1 antibody was raised against a 14 amino acid peptide from near the carboxy terminus of human Bfl-1.|
||WB: 0.5 - 2 ug/ml; IHC: 10ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column
|Homo sapiens BCL2-related protein A1 (BCL2A1), transcript variant 2|
|ACC-1; ACC-2; BCL2L5; BFL1; GRS; HBPA1|
Entrez Gene 597 Human
|Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells and is caused by caspase activation. Proteins that comprise the Bcl-2 family appear to control the activation of these enzymes. One such member is multi-domain antiapoptotic protein Bfl-1, which is overexpressed in stomach and other cancers. Bfl-1 can interact with Bax and suppress apoptosis by inhibiting the release of cytochrome c and caspase-3 activation. It is upregulated in cisplatin-resistant human bladder tumor, suggesting that its expression may be important for cisplatin resistance and inhibition of apoptosis in cancer cells. At least two isoforms of Bfl-1 are known to exist. Presumably due to post-translational modifications, Bfl-1 is often observed at higher molecular weight in SDS-PAGE than its predicted molecular weight would suggest.|
|Druggable Genome Metabolic pathways|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of Bfl-1 in human kidney tissue lysate with Bfl-1 antibody at (A) 0.5, (B) 1 and (C) 2 ug/ml.
Immunohistochemistry of Bfl-1 in mouse kidney tissue with Bfl-1 antibody at 10 ug/ml.